Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
08
06
2022
accepted:
09
11
2022
revised:
22
02
2023
pubmed:
10
2
2023
medline:
25
2
2023
entrez:
9
2
2023
Statut:
epublish
Résumé
Lassa virus (LASV), the cause of the acute viral hemorrhagic illness Lassa fever (LF), is endemic in West Africa. Infections in humans occur mainly after exposure to infected excrement or urine of the rodent-host, Mastomys natalensis. The prevalence of exposure to LASV in Sierra Leone is crudely estimated and largely unknown. This cross-sectional study aimed to establish a baseline point seroprevalence of IgG antibodies to LASV in three administrative districts of Sierra Leone and identify potential risk factors for seropositivity and LASV exposure. Between 2015 and 2018, over 10,642 participants from Kenema, Tonkolili, and Port Loko Districts were enrolled in this cross-sectional study. Previous LASV and LF epidemiological studies support classification of these districts as "endemic," "emerging," and "non-endemic", respectively. Dried blood spot samples were tested for LASV antibodies by ELISA to determine the seropositivity of participants, indicating previous exposure to LASV. Surveys were administered to each participant to assess demographic and environmental factors associated with a higher risk of exposure to LASV. Overall seroprevalence for antibodies to LASV was 16.0%. In Kenema, Port Loko, and Tonkolili Districts, seroprevalences were 20.1%, 14.1%, and 10.6%, respectively. In a multivariate analysis, individuals were more likely to be LASV seropositive if they were living in Kenema District, regardless of sex, age, or occupation. Environmental factors contributed to an increased risk of LASV exposure, including poor housing construction and proximity to bushland, forested areas, and refuse. In this study we determine a baseline LASV seroprevalence in three districts which will inform future epidemiological, ecological, and clinical studies on LF and the LASV in Sierra Leone. The heterogeneity of the distribution of LASV and LF over both space, and time, can make the design of efficacy trials and intervention programs difficult. Having more studies on the prevalence of LASV and identifying potential hyper-endemic areas will greatly increase the awareness of LF and improve targeted control programs related to LASV.
Sections du résumé
BACKGROUND
Lassa virus (LASV), the cause of the acute viral hemorrhagic illness Lassa fever (LF), is endemic in West Africa. Infections in humans occur mainly after exposure to infected excrement or urine of the rodent-host, Mastomys natalensis. The prevalence of exposure to LASV in Sierra Leone is crudely estimated and largely unknown. This cross-sectional study aimed to establish a baseline point seroprevalence of IgG antibodies to LASV in three administrative districts of Sierra Leone and identify potential risk factors for seropositivity and LASV exposure.
METHODOLOGY AND PRINCIPAL FINDINGS
Between 2015 and 2018, over 10,642 participants from Kenema, Tonkolili, and Port Loko Districts were enrolled in this cross-sectional study. Previous LASV and LF epidemiological studies support classification of these districts as "endemic," "emerging," and "non-endemic", respectively. Dried blood spot samples were tested for LASV antibodies by ELISA to determine the seropositivity of participants, indicating previous exposure to LASV. Surveys were administered to each participant to assess demographic and environmental factors associated with a higher risk of exposure to LASV. Overall seroprevalence for antibodies to LASV was 16.0%. In Kenema, Port Loko, and Tonkolili Districts, seroprevalences were 20.1%, 14.1%, and 10.6%, respectively. In a multivariate analysis, individuals were more likely to be LASV seropositive if they were living in Kenema District, regardless of sex, age, or occupation. Environmental factors contributed to an increased risk of LASV exposure, including poor housing construction and proximity to bushland, forested areas, and refuse.
CONCLUSIONS AND SIGNIFICANCE
In this study we determine a baseline LASV seroprevalence in three districts which will inform future epidemiological, ecological, and clinical studies on LF and the LASV in Sierra Leone. The heterogeneity of the distribution of LASV and LF over both space, and time, can make the design of efficacy trials and intervention programs difficult. Having more studies on the prevalence of LASV and identifying potential hyper-endemic areas will greatly increase the awareness of LF and improve targeted control programs related to LASV.
Identifiants
pubmed: 36758101
doi: 10.1371/journal.pntd.0010938
pii: PNTD-D-22-00744
pmc: PMC9946222
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0010938Informations de copyright
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Philos Trans R Soc Lond B Biol Sci. 2021 Nov 8;376(1837):20200362
pubmed: 34538146
J Virol. 2013 Oct;87(20):10918-35
pubmed: 23926354
PLoS Negl Trop Dis. 2020 Aug 26;14(8):e0008589
pubmed: 32845889
Infect Dis Poverty. 2016 Feb 25;5:17
pubmed: 26916067
Lancet Infect Dis. 2014 Apr;14(4):341-52
pubmed: 24631223
Philos Trans R Soc Lond B Biol Sci. 2019 Jun 24;374(1775):20180268
pubmed: 31056054
PLoS Negl Trop Dis. 2021 Jul 14;15(7):e0009576
pubmed: 34260615
Sci Rep. 2018 Apr 12;8(1):5939
pubmed: 29651117
Bull World Health Organ. 1982;60(2):253-60
pubmed: 6980735
NPJ Vaccines. 2018 Mar 20;3:11
pubmed: 29581897
Virol J. 2016 Oct 3;13(1):163
pubmed: 27716429
Int J Infect Dis. 2013 Nov;17(11):e1011-6
pubmed: 23871405
Bull World Health Organ. 1975;52(4-6):577-92
pubmed: 782738
Emerg Microbes Infect. 2020 Dec;9(1):1055-1064
pubmed: 32459576
Am J Trop Med Hyg. 1974 Nov;23(6):1131-9
pubmed: 4429182
PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005711
pubmed: 28671959
BMJ. 2003 Nov 29;327(7426):1271-5
pubmed: 14644972
BMC Infect Dis. 2019 Jul 10;19(1):606
pubmed: 31291900
Trans R Soc Trop Med Hyg. 2015 Aug;109(8):483-92
pubmed: 26085474
Expert Rev Vaccines. 2004 Apr;3(2):189-97
pubmed: 15056044
PLoS Negl Trop Dis. 2009 Nov 17;3(11):e548
pubmed: 19924222
Vector Borne Zoonotic Dis. 2001 Winter;1(4):283-97
pubmed: 12653128
Epidemiology. 2000 Nov;11(6):684-8
pubmed: 11055630
Emerg Microbes Infect. 2020 Dec;9(1):1761-1770
pubmed: 32723007
Clin Infect Dis. 2010 Dec 15;51(12):1435-41
pubmed: 21058912
J Clin Virol. 2006 Dec;37(4):277-81
pubmed: 16996789
BMC Infect Dis. 2019 Jul 19;19(1):647
pubmed: 31324229
Am J Trop Med Hyg. 1983 Jul;32(4):829-37
pubmed: 6881432
Emerg Infect Dis. 2014 Jul;20(7):1176-82
pubmed: 24959946
Zoonoses Public Health. 2012 Sep;59 Suppl 2:43-7
pubmed: 22958249
PLoS Curr. 2018 Jun 29;10:
pubmed: 30094105
Viruses. 2020 May 29;12(6):
pubmed: 32485952
Pathog Glob Health. 2017 Sep;111(6):276-288
pubmed: 28875769
Emerg Infect Dis. 2018 Jun;24(6):978-987
pubmed: 29775178
Curr Top Microbiol Immunol. 2002;262:75-109
pubmed: 11987809
Pan Afr Med J. 2018 May 24;30:56
pubmed: 30197747
Ann Clin Microbiol Antimicrob. 2021 Apr 24;20(1):29
pubmed: 33894784
Nat Commun. 2018 Oct 11;9(1):4223
pubmed: 30310067
Am J Trop Med Hyg. 2020 Nov 23;104(2):466-473
pubmed: 33236712
PLoS One. 2019 Mar 28;14(3):e0214284
pubmed: 30921383
Viruses. 2020 Mar 14;12(3):
pubmed: 32183319
mBio. 2012 Aug 14;3(4):e00180-12
pubmed: 22893382
PLoS Negl Trop Dis. 2021 Mar 17;15(3):e0009212
pubmed: 33730025
Influenza Other Respir Viruses. 2017 Jan;11(1):2-14
pubmed: 27417916
J Virol. 2000 Aug;74(15):6777-83
pubmed: 10888616
Int J Infect Dis. 2021 Feb;103:124-131
pubmed: 33176203
PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2748
pubmed: 24651047
Emerg Infect Dis. 2016 Apr;22(4):657-63
pubmed: 26981786
Microorganisms. 2021 Mar 12;9(3):
pubmed: 33809204
Emerg Infect Dis. 2019 Jun;25(6):1066-1074
pubmed: 31107222
Glob Health Action. 2014 May 15;7:23514
pubmed: 24848656
Emerg Infect Dis. 2019 Oct;25(10):1977-1979
pubmed: 31365854
Am J Trop Med Hyg. 2013 Feb;88(2):241-4
pubmed: 23390223
Nat Commun. 2021 Oct 1;12(1):5759
pubmed: 34599162
J Gen Virol. 2013 Jun;94(Pt 6):1206-1210
pubmed: 23468423
J Infect Dis. 1987 Mar;155(3):437-44
pubmed: 3805771
Euro Surveill. 2020 Apr;25(15):
pubmed: 32317052
Am J Trop Med Hyg. 2012 Aug;87(2):216-22
pubmed: 22855750
Cell. 2015 Aug 13;162(4):738-50
pubmed: 26276630
Am J Trop Med Hyg. 2007 Jul;77(1):169-75
pubmed: 17620650
Ecohealth. 2018 Jun;15(2):348-359
pubmed: 29572697
PLoS Med. 2007 Oct 16;4(10):e297
pubmed: 17941715
Int J Infect Dis. 2019 Jun;83:88-94
pubmed: 30930184
Health Secur. 2020 Jan;18(S1):S105-S112
pubmed: 32004125
Emerg Microbes Infect. 2019;8(1):640-649
pubmed: 31007139
Sci Rep. 2016 May 03;6:25280
pubmed: 27140942